Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Barchart · 4d ago

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness

Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.